Titre : ARN ribosomique 18S

ARN ribosomique 18S : Questions médicales fréquentes

Termes MeSH sélectionnés :

Reproducibility of Results
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "ARN ribosomique 18S : Questions médicales les plus fréquentes", "headline": "ARN ribosomique 18S : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les ARN ribosomique 18S : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-06-09", "dateModified": "2025-03-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "ARN ribosomique 18S" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "ARN ribosomique", "url": "https://questionsmedicales.fr/mesh/D012335", "about": { "@type": "MedicalCondition", "name": "ARN ribosomique", "code": { "@type": "MedicalCode", "code": "D012335", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D13.444.735.686" } } }, "about": { "@type": "MedicalCondition", "name": "ARN ribosomique 18S", "alternateName": "RNA, Ribosomal, 18S", "code": { "@type": "MedicalCode", "code": "D012337", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Harutaro Kenmotsu", "url": "https://questionsmedicales.fr/author/Harutaro%20Kenmotsu", "affiliation": { "@type": "Organization", "name": "Molecular Genetics Laboratory, Department of Applied Chemistry and Life Science, Toyohashi University of Technology, Toyohashi, Aichi, Japan." } }, { "@type": "Person", "name": "Yuu Hirose", "url": "https://questionsmedicales.fr/author/Yuu%20Hirose", "affiliation": { "@type": "Organization", "name": "Molecular Genetics Laboratory, Department of Applied Chemistry and Life Science, Toyohashi University of Technology, Toyohashi, Aichi, Japan." } }, { "@type": "Person", "name": "Toshihiko Eki", "url": "https://questionsmedicales.fr/author/Toshihiko%20Eki", "affiliation": { "@type": "Organization", "name": "Molecular Genetics Laboratory, Department of Applied Chemistry and Life Science, Toyohashi University of Technology, Toyohashi, Aichi, Japan." } }, { "@type": "Person", "name": "Ludivine Wacheul", "url": "https://questionsmedicales.fr/author/Ludivine%20Wacheul", "affiliation": { "@type": "Organization", "name": "RNA Molecular Biology, ULB Cancer Research Center (U-CRC), Centre for Microscopy and Molecular Imaging (CMMI), Fonds de la Recherche Scientifique (F.R.S.-FNRS), Université Libre de Bruxelles (ULB), Charleroi-Gosselies, Belgium." } }, { "@type": "Person", "name": "Anil Kumar Nehra", "url": "https://questionsmedicales.fr/author/Anil%20Kumar%20Nehra", "affiliation": { "@type": "Organization", "name": "Department of Veterinary Parasitology, Lala Lajpat Rai University of Veterinary and Animal Sciences, 125004, Hisar, Haryana, India. anilnehra15@gmail.com." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.", "datePublished": "2023-08-08", "url": "https://questionsmedicales.fr/article/37551542", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/dom.15217" } }, { "@type": "ScholarlyArticle", "name": "Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay.", "datePublished": "2023-03-09", "url": "https://questionsmedicales.fr/article/36892725", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10549-023-06888-1" } }, { "@type": "ScholarlyArticle", "name": "Reproducible Abnormalities and Diagnostic Generalizability of White Matter in Alzheimer's Disease.", "datePublished": "2023-04-04", "url": "https://questionsmedicales.fr/article/37014553", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12264-023-01041-w" } }, { "@type": "ScholarlyArticle", "name": "Support academic access to automated cloud labs to improve reproducibility.", "datePublished": "2023-01-03", "url": "https://questionsmedicales.fr/article/36595506", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pbio.3001919" } }, { "@type": "ScholarlyArticle", "name": "Reproducibility assessment of uptake on dedicated breast PET for noise discrimination.", "datePublished": "2022-11-25", "url": "https://questionsmedicales.fr/article/36434200", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12149-022-01809-6" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides nucléiques, nucléotides et nucléosides", "item": "https://questionsmedicales.fr/mesh/D009706" }, { "@type": "ListItem", "position": 3, "name": "Acides nucléiques", "item": "https://questionsmedicales.fr/mesh/D009696" }, { "@type": "ListItem", "position": 4, "name": "ARN", "item": "https://questionsmedicales.fr/mesh/D012313" }, { "@type": "ListItem", "position": 5, "name": "ARN ribosomique", "item": "https://questionsmedicales.fr/mesh/D012335" }, { "@type": "ListItem", "position": 6, "name": "ARN ribosomique 18S", "item": "https://questionsmedicales.fr/mesh/D012337" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : ARN ribosomique 18S - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur ARN ribosomique 18S", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur ARN ribosomique 18S", "description": "Comment détecte-t-on l'ARN ribosomique 18S ?\nQuels tests sont utilisés pour l'analyse de l'ARN 18S ?\nL'ARN 18S est-il spécifique à certaines espèces ?\nPeut-on quantifier l'ARN 18S ?\nQuels échantillons sont nécessaires pour l'analyse de l'ARN 18S ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Reproducibility+of+Results&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur ARN ribosomique 18S", "description": "Quels symptômes sont liés à des anomalies de l'ARN 18S ?\nL'ARN 18S affecte-t-il la santé cellulaire ?\nDes infections peuvent-elles influencer l'ARN 18S ?\nY a-t-il des signes de cancer liés à l'ARN 18S ?\nL'ARN 18S est-il impliqué dans des maladies neurodégénératives ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Reproducibility+of+Results&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur ARN ribosomique 18S", "description": "Comment prévenir les anomalies de l'ARN 18S ?\nL'éducation génétique peut-elle aider à prévenir des maladies liées à l'ARN 18S ?\nDes dépistages réguliers sont-ils recommandés ?\nLes vaccinations influencent-elles l'ARN 18S ?\nY a-t-il des recommandations alimentaires pour la santé de l'ARN 18S ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Reproducibility+of+Results&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur ARN ribosomique 18S", "description": "Quels traitements ciblent l'ARN 18S ?\nL'ARN 18S peut-il être utilisé en thérapie ?\nComment les antibiotiques affectent-ils l'ARN 18S ?\nY a-t-il des traitements pour les anomalies de l'ARN 18S ?\nLes thérapies ciblées peuvent-elles influencer l'ARN 18S ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Reproducibility+of+Results&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur ARN ribosomique 18S", "description": "Quelles complications peuvent survenir avec des anomalies de l'ARN 18S ?\nL'ARN 18S est-il lié à des complications respiratoires ?\nDes complications neurologiques peuvent-elles être liées à l'ARN 18S ?\nL'ARN 18S peut-il être impliqué dans des complications cancéreuses ?\nQuelles sont les complications métaboliques liées à l'ARN 18S ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Reproducibility+of+Results&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur ARN ribosomique 18S", "description": "Quels facteurs de risque sont associés à des anomalies de l'ARN 18S ?\nL'exposition à des toxines affecte-t-elle l'ARN 18S ?\nLe stress oxydatif influence-t-il l'ARN 18S ?\nDes habitudes alimentaires peuvent-elles influencer l'ARN 18S ?\nL'âge est-il un facteur de risque pour l'ARN 18S ?", "url": "https://questionsmedicales.fr/mesh/D012337?mesh_terms=Reproducibility+of+Results&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment détecte-t-on l'ARN ribosomique 18S ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'ARN 18S est souvent détecté par PCR ou séquençage pour identifier des organismes." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour l'analyse de l'ARN 18S ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent l'électrophorèse et l'hybridation pour évaluer la qualité de l'ARN." } }, { "@type": "Question", "name": "L'ARN 18S est-il spécifique à certaines espèces ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'ARN 18S présente des variations spécifiques aux espèces, utile pour l'identification." } }, { "@type": "Question", "name": "Peut-on quantifier l'ARN 18S ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la quantification se fait par RT-qPCR pour mesurer l'expression génique." } }, { "@type": "Question", "name": "Quels échantillons sont nécessaires pour l'analyse de l'ARN 18S ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des échantillons de tissus, cellules ou fluides biologiques sont requis pour l'analyse." } }, { "@type": "Question", "name": "Quels symptômes sont liés à des anomalies de l'ARN 18S ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies peuvent entraîner des troubles de croissance ou des maladies génétiques." } }, { "@type": "Question", "name": "L'ARN 18S affecte-t-il la santé cellulaire ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux d'ARN 18S peuvent perturber la synthèse protéique et la santé cellulaire." } }, { "@type": "Question", "name": "Des infections peuvent-elles influencer l'ARN 18S ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Certaines infections peuvent altérer l'expression de l'ARN 18S, affectant la réponse immunitaire." } }, { "@type": "Question", "name": "Y a-t-il des signes de cancer liés à l'ARN 18S ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux d'ARN 18S modifiés peuvent être associés à certains types de cancer." } }, { "@type": "Question", "name": "L'ARN 18S est-il impliqué dans des maladies neurodégénératives ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre l'ARN 18S et certaines maladies neurodégénératives." } }, { "@type": "Question", "name": "Comment prévenir les anomalies de l'ARN 18S ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne nutrition et un mode de vie sain peuvent aider à prévenir les anomalies génétiques." } }, { "@type": "Question", "name": "L'éducation génétique peut-elle aider à prévenir des maladies liées à l'ARN 18S ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation génétique permet de mieux comprendre les risques et de prendre des mesures préventives." } }, { "@type": "Question", "name": "Des dépistages réguliers sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des dépistages réguliers peuvent aider à identifier précocement des anomalies génétiques." } }, { "@type": "Question", "name": "Les vaccinations influencent-elles l'ARN 18S ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations peuvent indirectement influencer l'expression de l'ARN 18S en renforçant l'immunité." } }, { "@type": "Question", "name": "Y a-t-il des recommandations alimentaires pour la santé de l'ARN 18S ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en acides gras oméga-3 et en antioxydants peut soutenir la santé cellulaire." } }, { "@type": "Question", "name": "Quels traitements ciblent l'ARN 18S ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies géniques et des médicaments peuvent cibler l'expression de l'ARN 18S." } }, { "@type": "Question", "name": "L'ARN 18S peut-il être utilisé en thérapie ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des approches thérapeutiques exploitent l'ARN 18S pour traiter certaines maladies." } }, { "@type": "Question", "name": "Comment les antibiotiques affectent-ils l'ARN 18S ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains antibiotiques ciblent les ribosomes, affectant ainsi l'ARN 18S et la synthèse protéique." } }, { "@type": "Question", "name": "Y a-t-il des traitements pour les anomalies de l'ARN 18S ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements spécifiques peuvent être développés pour corriger les anomalies de l'ARN 18S." } }, { "@type": "Question", "name": "Les thérapies ciblées peuvent-elles influencer l'ARN 18S ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les thérapies ciblées peuvent moduler l'expression de l'ARN 18S dans certaines pathologies." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec des anomalies de l'ARN 18S ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des troubles métaboliques et des maladies héréditaires." } }, { "@type": "Question", "name": "L'ARN 18S est-il lié à des complications respiratoires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des études montrent un lien potentiel entre l'ARN 18S et certaines infections respiratoires." } }, { "@type": "Question", "name": "Des complications neurologiques peuvent-elles être liées à l'ARN 18S ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des anomalies de l'ARN 18S peuvent être associées à des troubles neurologiques." } }, { "@type": "Question", "name": "L'ARN 18S peut-il être impliqué dans des complications cancéreuses ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux d'ARN 18S sont souvent observés dans divers types de cancers." } }, { "@type": "Question", "name": "Quelles sont les complications métaboliques liées à l'ARN 18S ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des anomalies de l'ARN 18S peuvent entraîner des déséquilibres métaboliques et des syndromes." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à des anomalies de l'ARN 18S ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs génétiques, environnementaux et nutritionnels peuvent influencer l'ARN 18S." } }, { "@type": "Question", "name": "L'exposition à des toxines affecte-t-elle l'ARN 18S ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines peut altérer l'expression de l'ARN 18S et causer des dommages." } }, { "@type": "Question", "name": "Le stress oxydatif influence-t-il l'ARN 18S ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress oxydatif peut affecter la stabilité et l'expression de l'ARN 18S." } }, { "@type": "Question", "name": "Des habitudes alimentaires peuvent-elles influencer l'ARN 18S ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation déséquilibrée peut affecter l'expression de l'ARN 18S et la santé cellulaire." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque pour l'ARN 18S ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le vieillissement peut entraîner des modifications de l'expression de l'ARN 18S." } } ] } ] }

Sources (10000 au total)

Twelve-month results of the ADAPT randomized controlled trial: Reproducibility and sustainability of advanced hybrid closed-loop therapy outcomes versus conventional therapy in adults with type 1 diabetes.

To reassess the 6-month efficacy and to assess the 12-month sustained efficacy of the MiniMed™ 780G advanced hybrid closed-loop automated insulin delivery (AID) system compared to multiple daily injec... The ADAPT study was a prospective, multicentre, open-label, randomized control trial in people with type 1 diabetes, with a glycated haemoglobin (HbA1c) concentration of at least 8.0% (64 mmol/mol), o... A total of 39 SWITCH and 36 SUSTAIN participants entered the continuation phase. In the SWITCH group, HbA1c was significantly decreased by -1.4% (95% confidence interval [CI] -1.7% to -1.1%; P < 0.001... ADAPT study phase glycaemic improvements were reproduced and sustained in the continuation phase, supporting the early adoption of AID therapy in people with type 1 diabetes not meeting glucose target...

Reproducibility and intratumoral heterogeneity of the PAM50 breast cancer assay.

The PAM50 assay is used routinely in clinical practice to determine breast cancer prognosis and management; however, research assessing how technical variation and intratumoral heterogeneity contribut... We evaluated the impact of intratumoral heterogeneity on the reproducibility of results for the PAM50 assay by testing RNA extracted from formalin-fixed paraffin embedded breast cancer blocks sampled ... Technical replicates (N = 144) achieved 93% agreement for ROR-P group and 90% agreement on PAM50 subtype. For spatially distinct biological replicates (N = 40 intratumoral replicates), agreement was l... The PAM50 assay achieved very high technical reproducibility for breast cancer subtyping and ROR-P, but intratumoral heterogeneity is revealed by the assay in a small proportion of cases....

Reproducibility assessment of uptake on dedicated breast PET for noise discrimination.

Dedicated breast PET (dbPET) systems have improved the detection of small breast cancers but have increased false-positive diagnoses due to an increased chance of noise detection. This study examined ... This study included 21 patients with newly diagnosed breast cancer who underwent [... A total of 213 indexed uptake spots were identified on dbPET-1, including 152, 15, 6, 6, and 34 lesions classified as BI-RADS MRI categories 1, 2, 4b, 4c, and 5, respectively. Overall, 31.9% of the in... Our results demonstrated that reproducibility assessment helped reduce false-positive findings caused by noise on dbPET without lowering the sensitivity for malignancy. While subjective visual assessm...

Interlaboratory reproducibility of a touch-transfer assay for the assessment of antimicrobial surfaces.

Various assay methods have been developed to study antimicrobial activity based on contamination of surfaces with different amounts of liquid bacterial suspensions. Since surfaces with frequent hand c... To investigate a surface previously confirmed to display antimicrobial activity even after drying of small volumes of bacterial suspension (Egger antimicrobial surfaces: EAS) under conditions modellin... EAS, an antimicrobial copper alloy, as well as a negative control were examined to assess interlaboratory test reproducibility.... Significantly fewer bacteria on EAS after touch transfer and some differences in the touch transmission were detected between the two laboratories. However, an identical assessment of effectiveness fo... Since, in the real world of a hospital, organisms are typically transferred between dry surfaces, further standardization of the touch-transfer method is worthwhile for a better understanding of the e...

Repeatability and reproducibility of a hyperspectral imaging system for in vivo color evaluation.

Color imaging is a tried and true method for the evaluation of cosmetic and dermatological effects, but it fails to capture all the information in a scene's spectral reflectance. For this reason, ther... We developed a novel HyperSpectral Imager (HSI) able to take in vivo full-face format images as a next generation instrument for skin color measurement and beyond. Here, we report part of the results ... We find that the measurements from the HSI provide repeatability and reproducibility as good or better than those of our previous benchmark devices.... From these results, we conclude that not only is the HSI suitable for use in color evaluation studies, but also that it gives operational advantages over the previous generation of evaluation instrume...